MET and non-small cell lung carcinoma: However, MET overexpression in EGFRM+ NSCLC is not automatically associated with poor response to EGFR-TKIs, nor is an optimal predictor of response to MET-TKIs, as clinical responses to these drugs in NSCLC patients have been unsatisfactory in the absence of MET-mutation or -amplification [133,134].